Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shirya Rashid & John JP Kastelein. (2013) PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. Expert Review of Cardiovascular Therapy 11:11, pages 1567-1577.
Read now
Read now
Amanda J Hooper & John R Burnett. (2013) Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opinion on Biological Therapy 13:3, pages 429-435.
Read now
Read now
Amar M Salam. (2012) The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727. Expert Opinion on Investigational Drugs 21:10, pages 1585-1588.
Read now
Read now
John Jp Kastelein & Marjet Braamskamp. (2012) Pitavastatin: an overview of the LIVES study. Clinical Lipidology 7:sup1, pages 25-31.
Read now
Read now
André Marette & Gary Sweeney. (2011) Cardiovascular complications of diabetes: recent insights in pathophysiology and therapeutics. Expert Review of Endocrinology & Metabolism 6:5, pages 689-696.
Read now
Read now
Ravinder Malik & Ipsita Roy. (2011) Making sense of therapeutics using antisense technology. Expert Opinion on Drug Discovery 6:5, pages 507-526.
Read now
Read now
Articles from other publishers (32)
Lei Huang, Ying Cheng, Yulian Mu & Kui Li. (2023) PCSK9-D374Y Suppresses Hepatocyte Migration through Downregulating Free Cholesterol Efflux Rate and Activity of Extracellular Signal-Regulated Kinase. Analytical Cellular Pathology 2023, pages 1-11.
Crossref
Crossref
D Matías-Pérez, AD Pérez-Santiago, MA Sánchez Medina, JJ Alpuche Osorno & IA García-Montalvo. (2021)
PCSK9
gene participates in the development of primary dyslipidemias
. Balkan Journal of Medical Genetics 24:1, pages 5-14.
Crossref
Crossref
Seon-Ok Lee, Yinzhu Xu, Hengmin Han, Seok-Tae Jeong, You-Kyung Lee, Jean Kyung Paik, Jin-Sol Cha & Hyo-Jeong Lee. (2020) Fermented Rhus Verniciflua Stokes Extract Alleviates Nonalcoholic Fatty Liver through the AMPK/SREBP1/PCSK9 Pathway in HFD-Induced Nonalcoholic Fatty Liver Animal Model. Applied Sciences 10:19, pages 6833.
Crossref
Crossref
Fernando Riveros-Mckay, Clare Oliver-Williams, Savita Karthikeyan, Klaudia Walter, Kousik Kundu, Willem H. Ouwehand, David Roberts, Emanuele Di Angelantonio, Nicole Soranzo, John Danesh, Eleanor Wheeler, Eleftheria Zeggini, Adam S. Butterworth & Inês Barroso. (2020) The influence of rare variants in circulating metabolic biomarkers. PLOS Genetics 16:3, pages e1008605.
Crossref
Crossref
Chun‐wa Chung & Michael M. Hann. 2020. Structural Biology in Drug Discovery. Structural Biology in Drug Discovery
479
502
.
Alba Carreras, Luna Simona Pane, Roberto Nitsch, Katja Madeyski-Bengtson, Michelle Porritt, Pinar Akcakaya, Amir Taheri-Ghahfarokhi, Elke Ericson, Mikael Bjursell, Marta Perez-Alcazar, Frank Seeliger, Magnus Althage, Ralph Knöll, Ryan Hicks, Lorenz M. Mayr, Rosie Perkins, Daniel Lindén, Jan Borén, Mohammad Bohlooly-Y & Marcello Maresca. (2019) In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biology 17:1.
Crossref
Crossref
Matthieu Chodorge, Anthony J. Celeste, Joseph Grimsby, Anish Konkar, Pia Davidsson, David Fairman, Lesley Jenkinson, Jacqueline Naylor, Nicholas White, Jonathan C. Seaman, Karen Dickson, Benjamin Kemp, Jennifer Spooner, Emmanuel Rossy, David C. Hornigold, James L. Trevaskis, Nicholas J. Bond, Timothy B. London, Andrew Buchanan, Tristan Vaughan, Cristina M. Rondinone & Jane K. Osbourn. (2018) Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment. Scientific Reports 8:1.
Crossref
Crossref
Guo-Guang Sui, Hong-Bo Xiao, Xiang-Yang Lu & Zhi-Liang Sun. (2018) Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice. Journal of Agricultural and Food Chemistry 66:34, pages 8983-8990.
Crossref
Crossref
Ana Morales & Ray Hershberger. (2017) Clinical Application of Genetic Testing in Heart Failure. Current Heart Failure Reports 14:6, pages 543-553.
Crossref
Crossref
Nazish Khan & Helen Williams. (2015) Familial hyperlipidaemia. British Journal of Cardiac Nursing 10:8, pages 394-402.
Crossref
Crossref
K Gadkar, N Budha, A Baruch, J D Davis, P Fielder & S Ramanujan. (2014) A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations. CPT: Pharmacometrics & Systems Pharmacology 3:11, pages 1-9.
Crossref
Crossref
Shirya RashidHagai TavoriPatrick E. BrownMacRae F. LintonJane HeIlaria GiunzioniSergio Fazio. (2014) Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms. Circulation 130:5, pages 431-441.
Crossref
Crossref
Majambu Mbikay, Janice Mayne & Michel Chrétien. (2013) Proprotein Convertases Subtilisin/Kexin Type 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (第9型前蛋白转换酶-枯草溶菌素/蛋白酶K，一种酶转变的护送蛋白：在肝脏与肝外的功能). Journal of Diabetes 5:4, pages 391-405.
Crossref
Crossref
Maria Drakopoulou, Konstantinos Toutouzas & Christodoulos Stefanadis. (2013) Novel pharmacotherapies of familial hyperlipidemia. Pharmacology & Therapeutics 139:3, pages 301-312.
Crossref
Crossref
Li Shen, Hongchun Peng, Danyan Xu & Shuiping Zhao. (2013) The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors. Pharmacological Research 73, pages 27-34.
Crossref
Crossref
Michel Farnier. (2013) PCSK9 inhibitors. Current Opinion in Lipidology 24:3, pages 251-258.
Crossref
Crossref
A.L. Catapano & N. Papadopoulos. (2013) The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 228:1, pages 18-28.
Crossref
Crossref
Jennifer M. Lose, Michael P. Dorsch & Barry E. Bleske. (2013) Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low‐Density Lipoprotein Cholesterol Lowering. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:4, pages 447-460.
Crossref
Crossref
C. Stefanutti & U. Julius. (2013) Lipoprotein apheresis: State of the art and novelties. Atherosclerosis Supplements 14:1, pages 19-27.
Crossref
Crossref
Nabil G. Seidah. 2013. Handbook of Proteolytic Enzymes. Handbook of Proteolytic Enzymes
3315
3322
.
Michael T. Lipari, Wei Li, Paul Moran, Monica Kong-Beltran, Tao Sai, Joyce Lai, S. Jack Lin, Ganesh Kolumam, Jose Zavala-Solorio, Anita Izrael-Tomasevic, David Arnott, Jianyong Wang, Andrew S. Peterson & Daniel Kirchhofer. (2012) Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels. Journal of Biological Chemistry 287:52, pages 43482-43491.
Crossref
Crossref
ZHIHAN TANG, LU JIANG, JUAN PENG, ZHONG REN, DANGHENG WEI, CHUNYANG WU, LIHONG PAN, ZHISHENG JIANG & LUSHAN LIU. (2012) PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. International Journal of Molecular Medicine 30:4, pages 931-938.
Crossref
Crossref
Hong-Bo Xiao, Zhi-Liang Sun, Heng-Bo Zhang & Da-Sheng Zhang. (2012) Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacological Reports 64:4, pages 889-895.
Crossref
Crossref
Nabil G. Seidah & Annik Prat. (2012) The biology and therapeutic targeting of the proprotein convertases. Nature Reviews Drug Discovery 11:5, pages 367-383.
Crossref
Crossref
Lin-Zhang Huang & Hai-Bo Zhu. (2012) Novel LDL-oriented pharmacotherapeutical strategies. Pharmacological Research 65:4, pages 402-410.
Crossref
Crossref
Anna Raper, Daniel M. Kolansky & Marina Cuchel. (2011) Treatment of Familial Hypercholesterolemia: Is There a Need Beyond Statin Therapy?. Current Atherosclerosis Reports 14:1, pages 11-16.
Crossref
Crossref
Ioannis Papaioannou, J. Paul Simons & James S. Owen. (2012)
Targeted In Situ Gene Correction of Dysfunctional
APOE
Alleles to Produce Atheroprotective Plasma ApoE3 Protein
. Cardiology Research and Practice 2012, pages 1-16.
Crossref
Crossref
Arthur M Krieg. (2012) Targeting LDL Cholesterol With LNA. Molecular Therapy - Nucleic Acids 1, pages e6.
Crossref
Crossref
Sebastiano Calandra, Patrizia Tarugi, Helen E. Speedy, Andrew F. Dean, Stefano Bertolini & Carol C. Shoulders. (2011) Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk. Journal of Lipid Research 52:11, pages 1885-1926.
Crossref
Crossref
Willibald Hochholzer, David D. Berg & Robert P. Giugliano. (2011) The facts behind niacin. Therapeutic Advances in Cardiovascular Disease 5:5, pages 227-240.
Crossref
Crossref
Gerald F. Watts, David R Sullivan, Nicola Poplawski, Frank van Bockxmeer, Ian Hamilton-Craig, Peter M. Clifton, Richard O’Brien, Warrick Bishop, Peter George, Phillip J. Barter, Timothy Bates, John R. Burnett, John Coakley, Patricia Davidson, Jon Emery, Andrew Martin, Waleed Farid, Lucinda Freeman, Elizabeth Geelhoed, Amanda Juniper, Alexa Kidd, Karam Kostner, Ines Krass, Michael Livingston, Suzy Maxwell, Peter O’Leary, Amal Owaimrin, Trevor G. Redgrave, Nicola Reid, Lynda Southwell, Graeme Suthers, Andrew Tonkin, Simon Towler & Ronald Trent. (2011) Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements 12:2, pages 221-263.
Crossref
Crossref
Akl C Fahed & Georges M Nemer. (2011) Familial Hypercholesterolemia: The Lipids or the Genes?. Nutrition & Metabolism 8:1, pages 23.
Crossref
Crossref